A Study of Barzolvolimab in Patients With Atopic Dermatitis

Prior treatment

• Planned or anticipated use of any prohibited medications at any time during the study.
• Prior receipt of barzolvolimab or other anti-KIT therapy. There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Other illness

• Any other active pruritic skin diseases that would confound AD assessments based on the Investigator's clinical judgment.

Other

• Phototherapy with ultraviolet (UV) A or UVB within 4 weeks of Visit 1.

• Male or female ≥ 18 years of age
• Diagnosis of chronic atopic dermatitis (AD) for at least 1 year
• Onset of symptoms at least 1 year prior and current symptoms consistent with moderate to severe AD as defined by:
  • EASI ≥ 12 at Visit 1 and EASI ≥ 16 at Visit 2
  • Body Surface Area of Involvement (BSA) ≥ 10% at Visit 1 and Visit 2
  • IGA score ≥ 3 at Visit 1 and Visit 2
  • Severe itch, defined by weekly average of daily PP-NRS score of ≥ 5, during the 7 days prior to treatment
• Documented history of inadequate response to treatment with topical medications or for whom topical medications are otherwise medically inadvisable.
• Willing and able to complete a daily symptom electronic diary for the duration of the study and adhere to the study visit schedule.